Design Therapeutics, Inc.

For the period ended Sep 30, 2025. Filed Nov 5, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 5, 2025

DSGN$10.65-1.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Statements of Cash Flows

(in thousands)

	Nine Months Ended September 30,
	2025	2024
Cash flows from operating activities
Net loss	$(53,795)	$(35,937)
Reconciliation of net loss to net cash used in operating activities:
Depreciation	466	447
Stock-based compensation	11,114	9,601
Amortization of premiums on investment securities, net	(2,741)	(4,760)
Non-cash lease expense	(13)	9
Deferred financing costs	427	—
Change in operating assets and liabilities:
Prepaid expense and other assets	(496)	(379)
Accounts payable and other liabilities	2,646	(2,226)
Net cash used in operating activities	(42,392)	(33,245)
Cash flows from investing activities
Purchases of investment securities	(204,155)	(165,802)
Proceeds from maturities of investment securities	238,810	208,265
Purchases of property and equipment	(159)	(340)
Net cash provided by investing activities	34,496	42,123
Cash flows from financing activities
Issuance of common stock through employee stock purchase plan	361	223
Proceeds from the exercise of stock options	60	27
Net cash provided by financing activities	421	250
Net (decrease) increase in cash and cash equivalents	(7,475)	9,128
Cash and cash equivalents at beginning of period	22,563	21,200
Cash and cash equivalents at end of period	$15,088	$30,328

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.